Pricing Log in Create free account
Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue
+36.3%
EPS
+36.0%
Free cash flow
+3.85%
Total debt
−26.6%

Quarter to September 2026, against a year earlier

906.18 3.28 +0.36%
Market cap
$93.4B
P/E
19.2×
Fwd P/E
19.2×
Dividend yield
0.41%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. (REGN) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 6 added · 4 removed · 30 modified
P2I1A: no comparison — low extraction confidence
8-K Oct 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 1, 2026 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 8.01 Other events
8-K Sep 24, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
10-Q Jun 30, 2026 P1I2: 9 added · 4 removed · 24 modified
P2I1A: no comparison — low extraction confidence
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 2.02 Results of operations and financial condition
8-K Jun 12, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026 P1I2: 15 added · 24 removed · 39 modified
P2I1A: no comparison — low extraction confidence
8-K Apr 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 8, 2026 2.02 Results of operations and financial condition
10-K Dec 31, 2025 1: 27 added · 19 removed · 108 modified
1A: 16 added · 10 removed · 141 modified
7: 14 added · 17 removed · 29 modified
8-K Jan 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025 P1I2: 10 added · 2 removed · 26 modified
P2I1A: no comparison — low extraction confidence
8-K Oct 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2025 2.02 Results of operations and financial condition
10-Q Jun 30, 2025 P1I2: 11 added · 4 removed · 30 modified
P2I1A: no comparison — low extraction confidence
8-K Aug 1, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 4, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 13, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 7, 2024 2.02 Results of operations and financial condition
10-Q Jun 30, 2024
8-K Aug 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 8, 2024 2.02 Results of operations and financial condition
8-K May 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 8, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.